PL3125871T3 - Preparat mikrosfer PLGA zawierających peptyd o właściwościach kontrolowanego uwalniania - Google Patents

Preparat mikrosfer PLGA zawierających peptyd o właściwościach kontrolowanego uwalniania

Info

Publication number
PL3125871T3
PL3125871T3 PL14717411T PL14717411T PL3125871T3 PL 3125871 T3 PL3125871 T3 PL 3125871T3 PL 14717411 T PL14717411 T PL 14717411T PL 14717411 T PL14717411 T PL 14717411T PL 3125871 T3 PL3125871 T3 PL 3125871T3
Authority
PL
Poland
Prior art keywords
preparation
controlled release
release characteristics
plga microspheres
peptide loaded
Prior art date
Application number
PL14717411T
Other languages
English (en)
Inventor
Evangelos Karavas
Efthymios Koutris
Katerina MINIOTI
Sotiria Chaitidou
Georgia PAPANIKOLAOU
Theofanis MANTOURLIAS
Original Assignee
Pharmathen S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmathen S.A. filed Critical Pharmathen S.A.
Publication of PL3125871T3 publication Critical patent/PL3125871T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL14717411T 2014-03-31 2014-03-31 Preparat mikrosfer PLGA zawierających peptyd o właściwościach kontrolowanego uwalniania PL3125871T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14717411.4A EP3125871B1 (en) 2014-03-31 2014-03-31 Preparation of peptide loaded plga microspheres with controlled release characteristics
PCT/EP2014/000858 WO2015149820A1 (en) 2014-03-31 2014-03-31 Preparation of peptide loaded plga microspheres with controlled release characteristics

Publications (1)

Publication Number Publication Date
PL3125871T3 true PL3125871T3 (pl) 2021-04-19

Family

ID=50486884

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14717411T PL3125871T3 (pl) 2014-03-31 2014-03-31 Preparat mikrosfer PLGA zawierających peptyd o właściwościach kontrolowanego uwalniania

Country Status (23)

Country Link
US (1) US9943483B2 (pl)
EP (1) EP3125871B1 (pl)
JP (1) JP6494657B2 (pl)
KR (1) KR102218655B1 (pl)
CN (2) CN106170284A (pl)
AU (1) AU2014389015B2 (pl)
BR (1) BR112016022550B1 (pl)
CA (1) CA2944561C (pl)
CY (1) CY1124037T1 (pl)
DK (1) DK3125871T3 (pl)
EA (1) EA032580B1 (pl)
ES (1) ES2837044T3 (pl)
HR (1) HRP20210058T1 (pl)
HU (1) HUE052289T2 (pl)
LT (1) LT3125871T (pl)
MX (1) MX371139B (pl)
PL (1) PL3125871T3 (pl)
PT (1) PT3125871T (pl)
RS (1) RS61209B1 (pl)
SI (1) SI3125871T1 (pl)
SM (1) SMT202000692T1 (pl)
WO (1) WO2015149820A1 (pl)
ZA (1) ZA201607413B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2932532C (en) 2012-12-04 2021-06-22 Phosphorex, Inc. Microparticles and nanoparticles having negative surface charges
CN107106499B (zh) * 2014-11-02 2021-09-17 纳诺精密医疗有限公司 用于延长释放治疗剂的可植入医药装置
US12582607B2 (en) * 2014-11-02 2026-03-24 Nano Precision Medical, Inc. Implantable medical devices for extended release of therapeutic agents
KR102068578B1 (ko) * 2016-08-16 2020-01-21 중앙대학교 산학협력단 세포전달을 위한 다공성 마이크로스피어 및 이의 제조방법
JP2020513420A (ja) * 2016-12-12 2020-05-14 ホスホレックス、インコーポレイテッド 負の表面電荷を有するマイクロ粒子及びナノ粒子
CN108113975B (zh) * 2018-02-02 2020-10-09 中国人民解放军军事科学院军事医学研究院 一种基于涡漩振荡器的plga微球制备方法及其应用
KR101936040B1 (ko) * 2018-04-23 2019-01-08 주식회사 씨트리 안정화된 단상 혼합액을 이용하는 생분해성 미립구의 제조방법
CN109106688B (zh) * 2018-08-22 2021-08-17 丽珠医药集团股份有限公司 一种醋酸奥曲肽微球的制备方法
KR102181231B1 (ko) * 2018-11-22 2020-11-20 주식회사 메디포럼제약 로티고틴 함유 고분자 미립자의 제조방법
JP7600528B2 (ja) * 2020-03-16 2024-12-17 株式会社リコー 粒子の製造方法
US20210346296A1 (en) * 2020-05-08 2021-11-11 M. Technique Co., Ltd. A biologically active substance uniformly dispersed microsphere and a sustained release formulation comprising the same
CN119112804A (zh) * 2020-05-08 2024-12-13 M技术株式会社 均匀分散有生理活性物质的微球及含有其的缓释制剂
JP6852943B1 (ja) * 2020-05-08 2021-03-31 エム・テクニック株式会社 主剤が均一に分散されたマイクロスフェアー及びそれを含有する徐放性製剤
US12514908B2 (en) 2021-07-05 2026-01-06 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN116139256A (zh) * 2023-03-14 2023-05-23 复旦大学附属肿瘤医院 生长抑素/生长抑素类似物缓释膜及其制备方法和应用
CN120919405B (zh) * 2025-10-14 2025-12-16 渼颜空间生物科技(吉林)有限公司 一种pha微球、及其制备方法、含其制剂和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
US6913767B1 (en) * 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
AU6510400A (en) * 1999-08-04 2001-03-05 Oakwood Laboratories L.L.C. Slow release microspheres
DK1742616T3 (en) * 2004-04-30 2015-01-12 Abraxis Bioscience Llc The microsphere-discharge-system for the prolonged delivery and methods of making and using the same
US20100086597A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for the sustained release of octreotide with a low initial burst
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
AR074603A1 (es) * 2008-12-15 2011-01-26 Novartis Ag Formulacion de deposito de octreotida con niveles de exposicion constantemente altos.uso. metodo. kit

Also Published As

Publication number Publication date
LT3125871T (lt) 2020-12-28
RS61209B1 (sr) 2021-01-29
MX371139B (es) 2020-01-20
JP2017509661A (ja) 2017-04-06
HRP20210058T1 (hr) 2021-03-05
SMT202000692T1 (it) 2021-01-05
KR20160137608A (ko) 2016-11-30
HUE052289T2 (hu) 2021-04-28
ZA201607413B (en) 2018-11-28
JP6494657B2 (ja) 2019-04-03
DK3125871T3 (da) 2020-12-21
BR112016022550A2 (pl) 2017-08-15
KR102218655B1 (ko) 2021-02-22
AU2014389015A1 (en) 2016-09-29
US9943483B2 (en) 2018-04-17
PT3125871T (pt) 2021-01-06
SI3125871T1 (sl) 2021-03-31
WO2015149820A1 (en) 2015-10-08
EP3125871A1 (en) 2017-02-08
CA2944561A1 (en) 2015-10-08
EP3125871B1 (en) 2020-10-21
AU2014389015B2 (en) 2019-05-09
MX2016012846A (es) 2017-05-09
CN106170284A (zh) 2016-11-30
CA2944561C (en) 2019-06-18
CN114191538A (zh) 2022-03-18
BR112016022550B1 (pt) 2023-03-28
US20170281547A1 (en) 2017-10-05
ES2837044T3 (es) 2021-06-29
EA032580B1 (ru) 2019-06-28
EA201691884A1 (ru) 2017-02-28
CY1124037T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
ZA201607413B (en) Preparation of peptide loaded plga microspheres with controlled release characteristics
IL280485A (en) Sustained-release pridopidine preparations
GB201611990D0 (en) Metabolic drug loading of EVs
GB201413564D0 (en) Time of flight determination
IL252220B (en) Low density microspheres
IL257026A (en) Solid state forms of eluxadoline
IL251216A0 (en) Injectable microparticles for hyperlocal release of medicinal agents
SI3845221T1 (sl) Trdne oblike sofosbuvirja
IL266022A (en) Capsule with controlled release
HUE052386T2 (hu) Hatóanyagok felszabadítására szolgáló szemcsék
GB201522441D0 (en) Sustained release cyclosporine-loaded microparticles
SG11201607624VA (en) Anchor
DK3130334T3 (da) Fast præparat til kontrolleret frigivelse med delvis coating
IL246979A0 (en) Crystalline forms of sofosbuvir
SI3145497T1 (sl) Obložene kapsule s prirejenim sproščanjem
SI3145499T1 (sl) Obložene kapsule s prirejenim sproščanjem
EP3178471A4 (en) Preparation method of drug-containing sustained release microparticles
IL251946B (en) Process for making micro particles
GB2526567B (en) Anchor
IL249130A0 (en) Preparation of piperidine-4-carbthioamide
IL256492B1 (en) Crystal structures of linklutides
IL249332A0 (en) Crystalline forms of sofosbuvir
HK1234993A1 (en) Injectable microparticles for hyper-localized release of therapeutic agents
TWM489230U (en) Improved structure of pin set
TWM489582U (en) Improved structure of cup